Cognition Therapeutics, Inc. (CGTX) has a negative trailing P/E of -3.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -29.17%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -40.3 | 0.00 | -4.79 | 0.00 | - |
| 2020 | -27.8 | -0.39 | -4.11 | 0.00 | - |
| 2021 | -12.0 | -0.37 | 2.74 | 0.00 | - |
| 2022 | 80.4 | 58.71 | 1.51 | 0.00 | - |
| 2023 | -2.2 | -0.13 | 2.27 | 0.00 | - |
| 2024 | -0.8 | 0.71 | 1.49 | 0.00 | - |
| 2025 | -4.2 | 0.07 | 2.87 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.32 | $0.00 | $-6.95M | - |
| 2020 | $-0.46 | $0.00 | $-10.07M | - |
| 2021 | $-0.46 | $0.00 | $-10.29M | - |
| 2022 | $0.03 | $0.00 | $757K | - |
| 2023 | $-0.86 | $0.00 | $-25.79M | - |
| 2024 | $-0.86 | $0.00 | $-33.97M | - |
| 2025 | $-0.32 | $0.00 | $-23.49M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.33 | $-0.47 – $-0.14 | $18.7M | $18.7M – $18.7M | 4 |
| 2027 | $-0.35 | $-0.58 – $-0.22 | $41.93M | $41.93M – $41.93M | 3 |
| 2028 | $-0.64 | $-0.64 – $-0.64 | $4.3M | $4.3M – $4.3M | 1 |
| 2029 | $-0.55 | $-0.55 – $-0.55 | $63.7M | $63.7M – $63.7M | 1 |
| 2030 | $-0.19 | $-0.19 – $-0.19 | $112.5M | $112.5M – $112.5M | 1 |
